With the antibody drug conjugate market projected to hit $28 billion by 2028, some companies are looking to harness the drugs for immunotherapy.
Tag Archive for: antibody-drug conjugates
Due to Bristol Myers Squibb’s ongoing portfolio reprioritization, Eisai is taking over the development and commercialization of farletuzumab ecteribulin, an investigational antibody-drug conjugate targeting solid tumors.
The facility, which will be the drugmaker’s first end-to-end antibody-drug conjugate production site, will be supported by the Singapore Economic Development Board.
With the investment in the plant, Daiichi Sankyo is looking to create new laboratories for its antibody drug conjugates used to develop and manufacture therapies for breast, lung and stomach cancers.
Ambrx is developing therapies that belong to the class of drugs called antibody drug conjugates (ADC), which are described by researchers as “guided missiles” to target cancer cells and minimize damage to healthy tissue.
At this year’s European Society for Medical Oncology, excitement topped 2022 levels on NSCLC and breast cancer innovation.
The deal would help boost AbbVie’s plans to expand into the cancer drug market as its top-selling product Humira, a rheumatoid arthritis treatment, faces fierce competition in the United States.
GSK said on that its blood cancer drug Blenrep had reached a key goal in a late-stage trial, as the British drugmaker looks to bolster its oncology business after a series of setbacks.
Looking beyond the coronavirus business, the company has renewed its focus on a growing development pipeline in oncology, which includes use of the mRNA technology pioneered in the vaccine as well as precision anti-cancer drugs from a class known as antibody-drug conjugates and therapies based on modified immune cells.
The move comes days after Merck said it would pay Daiichi Sankyo $5.5 billion to jointly develop three of its candidate cancer drugs in a deal that could be worth up to $22 billion for the Japanese firm.